Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.
The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
